SNJEŽANA KAŠTELAN^1,2, ANA DIDOVIĆ PAVIČIĆ³, DARIA PAŠALIĆ⁴, TAMARA NIKUŠEVA-MARTIĆ⁵, SAMIR ČANOVIĆ^3,7, PETRA KOVAČEVIĆ^1,6,*, SUZANA KONJEVODA^3,7

Oncology Research, Vol.32, No.8, pp. 1265-1285, 2024, DOI:10.32604/or.2024.048437

Abstract Uveal and conjunctival melanomas are relatively rare tumors; nonetheless, they pose a significant risk of mortality for a large number of affected individuals. The pathogenesis of melanoma at different sites is very similar, however, the prognosis for patients with ocular melanoma remains unfavourable, primarily due to its distinctive genetic profile and tumor microenvironment. Regardless of considerable advances in understanding the genetic characteristics and biological behaviour, the treatment of uveal and conjunctival melanoma remains a formidable challenge. To enhance the prospect of success, collaborative efforts involving medical professionals and researchers in the fields of ocular biology… More > Graphic Abstract

Xuyang Wen^*, Xiaoping He^†, Feng Jiao^‡, Chunhui Wang^§, Yang Sun^‡, Xuequn Ren^¶, Qianwen Li^*

Oncology Research, Vol.25, No.4, pp. 629-640, 2017, DOI:10.3727/096504016X14768383625385

Abstract Gastric cancer (GC) is one of the main causes of cancer death. The tumor microenvironment has a profound effect on inducing tumor growth, metastasis, and immunosuppression. Fibroblast activation protein-a (FAP) is a protein that is usually expressed in fibroblasts, such as cancer-associated fibroblasts, which are major components of the tumor microenvironment. However, the role of FAP in GC progression and treatment is still unknown. In this study, we explored these problems based on GC patient samples and experimental models. We found that high FAP expression was an independent prognosticator of poor survival in GC patients. More >

Xiaolin Miao^*1, Yiqi Chen^*1, Ke Hao^†1, Meiqin Zheng^‡, Bingyu Chen^†, Kaiqiang Li^†, Ying Wang^†, Wei Zhang^§, Yu Zhang^§, Xiaozhou Mou^§, Shanshan Jiang^¶, Zhen Wang^‡§

Oncology Research, Vol.26, No.2, pp. 173-182, 2018, DOI:10.3727/096504017X14841698396865

Abstract Glioblastoma is a lethal disease featuring a high proliferation of tumor cells, excessive angiogenesis, and heavy drug resistance. The overall survival of glioblastoma patients has been dismal, even with an intensive standard of care. Recent advances in immune checkpoint blockades are changing the treatment of cancers. However, the efficacy of immune checkpoint blockades in glioblastoma is still unclear. Here we investigated the roles of CD103⁺ cells in regulating the effect of immune checkpoint blockades in glioblastoma mouse models. Our findings indicated that the murine glioblastoma model was not sensitive to immune checkpoint blockades. Flt3L, a growth More >

KAIWEN TIAN^#, HANZHONG CHEN^#, QIANQIAN WANG, FENGLIAN JIANG, CHUNXIANG FENG, TENG LI, XIAOYONG PU, YANLIN TANG^*, JIUMIN LIU^*

BIOCELL, Vol.48, No.5, pp. 817-834, 2024, DOI:10.32604/biocell.2024.048737

Abstract Background: The incidence of clear cell renal cell carcinoma (ccRCC) is globally high; however, despite the introduction of innovative drug therapies, there remains a lack of effective biomarkers for evaluating treatment response. Recently, Caspase recruiting domain-containing protein 11 (CARD11) has garnered attention due to its significant association with tumor development and the immune system. Methods: The expression of CARD11 mRNA and protein in ccRCC were analyzed by public database and immunohistochemistry. The focus of this study is on the epigenomic modifications of CARD11, its expression of ccRCC immunophenotype, and its correlation with response to immunotherapy… More > Graphic Abstract

HAO LV¹, BO ZHU^1,2, DEGAO CHEN^1,2,*

BIOCELL, Vol.48, No.3, pp. 363-378, 2024, DOI:10.32604/biocell.2023.046367

Abstract Tumor-associated macrophages (TAMs) are emerging as targets for tumor therapy because of their primary role in promoting tumor progression. Several studies have been conducted to target TAMs by reducing their infiltration, depleting their numbers, and reversing their phenotypes to suppress tumor progression, leading to the development of drugs in preclinical and clinical trials. However, the heterogeneous characteristics of TAMs, including their ontogenetic and functional heterogeneity, limit their targeting. Therefore, in-depth exploration of the heterogeneity of TAMs, combined with immune checkpoint therapy or other therapeutic modalities could improve the efficiency of tumor treatment. This review focuses More >

XIAN ZHANG¹, ZHUANG ZHOU², JUNZHE WANG¹, MENGMENG HAN¹, HAN LIU¹, MEIRONG ZANG¹, JIANNING LIU¹, JIAPEI LU¹, JINQIAO ZHANG¹, GUOCHUAN ZHANG^2,*, LIXIA SUN^1,#,*

BIOCELL, Vol.48, No.2, pp. 303-311, 2024, DOI:10.32604/biocell.2023.046640

Abstract Background: Prognosis of multiple myeloma (MM) patients with extramedullary disease (EMD) remains poor. T cell dysfunction and an immunosuppressive environment have been reported in the bone marrow (BM) of MM patients. However, the immunosuppressive microenvironment and immune checkpoint receptors (ICRs) on CD8 T cells in the EMD tissue of newly diagnosed MM (NDMM) patients have not been thoroughly studied. Methods: We investigated the expression levels of T cell immunoglobulin mucin-domain-containing-3 (TIM-3) and T-cell immunoglobulin and ITIM domain (TIGIT) on CD8 T cells and the expression of their ligands (Galectin-9 and CD155) on myeloma cells in… More > Graphic Abstract

HONGYUAN LIANG^1,#, YANQIU LI^2,#, YONGGANG QU³, LINGYUN ZHANG^4,*

Oncology Research, Vol.32, No.2, pp. 393-407, 2024, DOI:10.32604/or.2023.031134

Abstract Advanced LUAD shows limited response to treatment including immune therapy. With the development of sequencing omics, it is urgent to combine high-throughput multi-omics data to identify new immune checkpoint therapeutic response markers. Using GSE72094 (n = 386) and GSE31210 (n = 226) gene expression profile data in the GEO database, we identified genes associated with lung adenocarcinoma (LUAD) death using tools such as “edgeR” and “maftools” and visualized the characteristics of these genes using the “circlize” R package. We constructed a prognostic model based on death-related genes and optimized the model using LASSO-Cox regression methods.… More >

WENFEI GE^1,#, SHIYAN SONG^1,#, XIAOCHEN QI^1,#, FENG CHEN^1,#, XIANGYU CHE¹, YONGHAO SUN¹, JIN WANG¹, XIAOWEI LI², NANA LIU³, QIFEI WANG^1,*, GUANGZHEN WU^1,*

Oncology Research, Vol.31, No.3, pp. 255-270, 2023, DOI:10.32604/or.2023.027942

Abstract As a common tumor of the urinary system, the morbidity and mortality related to renal carcinoma, are increasing annually. Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell carcinoma, accounting for approximately 75% of the total number of patients with renal cell carcinoma. Currently, the clinical treatment of ccRCC involves targeted therapy, immunotherapy, and a combination of the two. In immunotherapy, PD-1/PD-L1 blocking of activated T cells to kill cancer cells is the most common treatment. However, as treatment progresses, some patients gradually develop resistance to immunotherapy. Meanwhile, other patients More > Graphic Abstract

KAIMIN FAN, JUNWEI WENG^*

BIOCELL, Vol.47, No.6, pp. 1199-1211, 2023, DOI:10.32604/biocell.2023.028516

Abstract Immunotherapy targets the dysfunctional immune system to induce cancer cell killing by CD8-positive T cells. Immune checkpoint inhibitors (ICIs), specifically anti-PD-1 antibodies, anti-PD-L1 antibodies, and anti-CTLA4 antibodies, have revolutionized the management of many malignancies due to their significant role in generating a durable clinical response. However, clinical data suggest that response rates to ICI monotherapy are low due to the immunologically silent characteristics of breast cancer (BC). Chemotherapy, surgery, radiotherapy, and targeted therapy were recently reported to alter the tumor microenvironment and enhance the ICI response. Some clinical studies supported that ICIs, in combination with More >

YANYA CHEN^1,#, HONGYUAN WU^2,#, RUISI ZHOU^5,#, HELING DONG⁴, XUEFANG ZHANG², XUEWEI WU¹, WENSHAN CHEN¹, YANTING YOU^5,*, YIFEN WU^3,*

BIOCELL, Vol.47, No.6, pp. 1353-1364, 2023, DOI:10.32604/biocell.2023.027346

Abstract Background: The relationship between microRNA (miRNA) expression patterns and tumor mutation burden (TMB) in uterine corpus endometrial carcinoma (UCEC) was investigated in this study. Methods: The UCEC dataset from The Cancer Genome Atlas (TCGA) database was used to identify the miRNAs that differ in expression between high TMB and low TMB sample sets. The total sample sets were divided into a training set and a test set. TMB levels were predicted using miRNA-based signature classifiers developed by Lasso Cox regression. Test sets were used to validate the classifier. This study investigated the relationship between a miRNA-based signature… More >